Acute Promyelocytic Leukaemia: An Experience with 6 Cases
DOI:
https://doi.org/10.3329/jom.v12i2.8420Keywords:
Acute promyelocytic leukaemia, PML/RARA fusion protein, All- trans retinoic acid (ATRA)Abstract
Background and objective: Acute promyelocytic leukaemia (APL) is considered a distinct entity among the acute myeloid leukemias (AML). Our purpose is to see its clinical presentations and outcome with ATRA (all- trans retinoic acid).
Materials and methods: It is a retrospective descriptive study of 6 patients diagnosed by cytologic criteria between November 2008 and February 2011 in two tertiary care hospitals in Dhaka, Bangladesh. All specific information were recorded in standardized data sheet and analyzed manually.
Results: Mean (SD) age of patients was 28.6 (±7.84) years with equal gender distribution. Fever >101°F, weakness, easy fatigability, and bleeding manifestations were common presentations (100%). The other manifestations were bony tenderness, purpuric spots or DIC, but no lymphadenopathy and organomegaly were seen. Mean (±SD) Hb was 9.03 (±1.06) gm/dl, in 66% ESR was >50mm in 1st hr with 50% leukocytosis and 50% leucopenia but 100% thrombocytopenia.In the peripheral blood 40%-85% of the leukocytes were blast cells. Bone marrow was done in all cases which suggested AML-M3 (Acute promyelocytic leukemia) and cytogenetic diagnosis were done in 3 cases, which showed t(15;17)PML-RARA fusion protein positive. ATRA (all-trans retinoic acid) plus chemotherapy (daunorubicin ± cytarabine) achieved complete remission in 5 (80%) patients.
Conclusion: Modern treatment is highly effective if administered early.
Keyword: Acute promyelocytic leukaemia, PML/RARA fusion protein, All- trans retinoic acid (ATRA).
DOI: http://dx.doi.org/10.3329/jom.v12i2.8420
JOM 2011; 12(2): 139-141
Downloads
112
67
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).